Access & coverage
Tax-funded + private optional
Public system + Pharmac drug agency; private optional
Treatment
- Specialist centers for rare / congenital conditions
- Supportive and palliative care when curative options are limited
- Case management across social and medical services
Prevention
- Antenatal care; newborn screening where relevant
- Public-health programs aimed at the specific residual causes
- Social supports that reduce vulnerability
Lifestyle
- Cause-specific advice via primary care
- Family education for congenital / neonatal survivors
- Avoidance of known toxins / teratogens
What stands out here
Same broad other toolkit as peers — differences are coverage rules, wait times, prices, and follow-through.
vs master: -0.0 percentage points vs Top 20 average share.